Opinion|Videos|December 3, 2024

Clinical Experience in CAR-T-Cell Therapy in Early Relapsed MM and Insights From the CARTITUDE-4 Trial

Author(s)Morie A. Gertz, MD, MACP, Mayo Clinic, Ajai Chari, MD

Panelists discuss how chimeric antigen receptor (CAR) T-cell therapy in early relapsed multiple myeloma can provide deep and durable responses for eligible patients, though patient selection, timing of referral, manufacturing logistics, and management of adverse effects remain important considerations in optimizing outcomes.

Episodes in this series

2 experts are featured in this series.

EP. 1 Current Strategies for Frontline Therapy in Transplant-Preferred NDMM

2 experts are featured in this series.

EP. 2 Brief Overview of PERSEUS, IsKia, and CASSIOPEIA Clinical Trials

2 experts are featured in this series.

EP. 3 Deciding Between Quadruplet and Triplet Therapy in Transplant-Preferred NDMM: Key Considerations

2 experts are featured in this series.

EP. 4 Insights of MAIA, BENEFIT, and IMROZ Trials on Frontline Treatment for Transplant Not-Preferred NDMM

2 experts are featured in this series.

EP. 5 Initial Impressions of the CEPHEUS Clinical Trial in Transplant Not-Preferred NDMM

2 experts are featured in this series.

EP. 6 Clinical Experience in CAR-T-Cell Therapy in Early Relapsed MM and Insights From the CARTITUDE-4 Trial

Video content above is prompted by the following:

What has been your experience with using CAR T-cell therapy in patients with early relapsed multiple myeloma?
How does CAR T-cell therapy compare with other available second-line treatments?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

November 4th, 2026

CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma

In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

October 29th, 2026

Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?

“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.

Trending on CancerNetwork

Building Systems to Catch Liver and Other Cancers in Patients With MASLD

Closing the HCC Surveillance Gap in MASLD Without Cirrhosis

Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC

Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis

Changing Mindsets and Removing Guilt Surrounding Lung Cancer Diagnoses